A tighter archive for life-science signals.
Search once, then narrow by source or topic.
FDA lifts partial hold on Merck, Daiichi's Phase 3 lung cancer study
FDA lifts partial hold on Merck, Daiichi's Phase 3 lung cancer study
Walmart makes tepid return to healthcare
Walmart makes tepid return to healthcare
Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report
Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report
AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGen
AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGen
Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratory
Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratory
FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus
FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus
Arkin Capital raises $100M to back a dozen early-stage biotechs
Arkin Capital raises $100M to back a dozen early-stage biotechs
#JPM26: Moderna CEO Bancel talks deals, flu and RSV strategy
#JPM26: Moderna CEO Bancel talks deals, flu and RSV strategy
Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Kinaset rakes in $103M to advance inhaled asthma drug
Kinaset rakes in $103M to advance inhaled asthma drug
Signal Pulse Poll: What's the mood going into JPM?
Signal Pulse Poll: What's the mood going into JPM?
Private and public biotechs go on $4.9B funding spree ahead of JPM
Private and public biotechs go on $4.9B funding spree ahead of JPM
Biotech's 2026 outlook: Six questions for the year ahead
Biotech's 2026 outlook: Six questions for the year ahead
Mirador raises $250M, with plans to become an immunology powerhouse
Mirador raises $250M, with plans to become an immunology powerhouse
Genentech CEO says pharmacy benefit manager shift will save $70M
Genentech CEO says pharmacy benefit manager shift will save $70M
Hair growth biotech Veradermics files for IPO to fund oral Rogaine
Hair growth biotech Veradermics files for IPO to fund oral Rogaine
US slashes vaccine schedule; Every drug approval from 2025; argenx’s new CEO; and more
US slashes vaccine schedule; Every drug approval from 2025; argenx’s new CEO; and more
Eikon Therapeutics files for IPO, testing biotech rally
Eikon Therapeutics files for IPO, testing biotech rally
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page